^
    Back
    Association details:
    Biomarker:NRAS Q61R
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    EADO-WCM 2021
    Title:

    P-071 Use of checkpoint inhibitors in hereditary angioedema patient with melanoma: first world case report.

    Published date:
    04/15/2021
    Excerpt:
    A 60-years-old woman presented in July 2020 with a painful subscapular dorsal mass... she was diagnosed from primary fusocellular melanoma... molecular testing confirmed the presence of NRAS p.Q61R...Nivolumab 3mg/kg in combination with ipilimumab 1mg/kg treatment was initiated....After 6thcycle of treatment, on 08 February, a PET CT performed showing complete response (CR) of disease.